5.1 Section 7(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication.
5.2 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraph above. This means that, if a patient has transfusion‑dependent anaemia caused by low or intermediate‑1‑risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality and the doctor responsible for their care thinks that lenalidomide is the right treatment, it should be available for use, in line with NICE's recommendations.
5.3 The Department of Health and the company have agreed that lenalidomide will be available to the NHS with a patient access scheme. This patient access scheme ensures that the drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the company. It is the responsibility of the company to communicate with the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to Sujith Dhanasiri, 01753498600, email@example.com
5.4 NICE has developed a costing template to estimate the national and local savings and costs associated with implementation.